Depressive disorders are a great burden for individual patients and society. Blood-based biomarkers are regarded as a feasible option for investigation of depressive disorders. Several potential biomarkers for depression were selected. We studied the following serum markers: cortisol, melatonin, brain-derived neurotrophic factor (BDNF), prolactin, insulin-like growth factor 1 (IGF-1), β-endorphin, orexin A. The patient sample consisted of 78 persons with depressive disorders. Patients were divided into two groups: 46 patients with a first depressive episode and 32 patients with recurrent depressive disorder. Control group consisted of 71 healthy individuals of corresponding age and sex. All markers were measured in serum using MILLIPLEX® MAP panels (Merck, Darmstadt, Germany) by analyzer MAGPIX (Luminex, USA). Statistical analyses were performed using SPSS software. Results were expressed as median and quartile intervals [Q1–Q3]. There was a significant increase of serum concentrations of cortisol (663.69 [467.5–959.49] nmol/L, P = 0.029) and melatonin (61.31 [33.6–132.59] pg/mL, P = 0.029) in patients compared with the control group (526.1 [367.24–654.7] nmol/L and 45.11 [27.47–73.47] pg/mL). In addition, correlations were found between potential biomarkers, clinical indicators and treatment response measured by applying the Hamilton Depression rating scale and the Clinical Global Impression rating scales. A significant correlation was found between the concentration of prolactin and high response to pharmacotherapy (r = –0.267, P = 0.029). Identifying biomarkers that can be used as diagnostics or predictors of treatment response in people with depressive disorders will be an important step towards being able to provide personalized treatment.

Disclosure of interest The work is supported by the project of Russian Foundation of Basic Research № 14-04-01157a.
EV0372
Management of treatment resistant depression: A comparison between French expert consensus guidelines and international evidence based guidelines

T. Charpeaud 1,2, A. Yrondi 2, W. El-Hage 1, M. Leboyer 4, E. Haffen 5, P.M. Llorca 1, P. Courtet 6, B. Aouizerate 7
1 CHU de Clermont-Ferrand, service de psychiatrie de l’adulte B, Clermont-Ferrand, France
2 CHU de Toulouse, service de psychiatrie de l’adulte, Toulouse, France
3 CHU de Tours, service de psychiatrie de l’adulte, Tours, France
4 Centre hospitalier Albert-Chenevier, service de psychiatrie de l’adulte, Créteil, France
5 CHU de Besançon, service de psychiatrie de l’adulte, Besançon, France
6 CHU de Montpellier, urgences et post-urgences, Montpellier, France
7 Centre hospitalier Charles-Perrens, pôle de psychiatrie, Bordeaux, France
* Corresponding author.

Expert consensus guidelines rely on a relevant methodological procedure complementary to based-evidence recommendations. They aim at offering support strategies derived from expert consensus for clinical situations where the levels of evidence are either absent or insufficient. Recommendations for resistant depressive disorders proposed by French association for biological psychiatry and fundamental foundation, were based on responses from 36 highly specialized experts in this field. They were invited to complete a comprehensive questionnaire with 118 issues. The questions raised covered a wide range of aspects from the evaluation of therapeutic resistance and clinical conditions increasing the risk for treatment failure to the adopted therapeutic strategies organized according the effects of previous treatment lines. Specific populations/situations especially including elderly, comorbidities (anxiety disorders, personality disorders and addictions) were also been studied through specific questions. Such recommendations are intended to substantially help the decision and therapeutic choice of clinician implied in the management of resistant depressive disorders in everyday clinical practice. We propose in this communication to compare the results of these recommendations with the various data from the evidence-based guidelines in order to demonstrate their complementarity for the management of resistant depressive disorders.

Disclosure of interest The authors have not supplied their declaration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.702

EV0373
Electroconvulsive therapy as an effective alternative in depressive disorder

G.M. Chauca Chauca 1,∗, L. Carrió Expósito 1, P. Alonso Lobato 2
1 UGC-Salud Mental Hospital Infantia Margarita, Cabra, Córdoba, Spain
2 UGC-Salud Mental Área Sanitaria Norte, Peñarroya, Córdoba, Spain
* Corresponding author.

Introduction The efficacy of electroconvulsive therapy (ECT) in the treatment of depressive episodes is well established, and so is reflected in the major guides.

Objectives Description of a clinical case of a patient diagnosed with major depressive episode with psychotic symptoms and obsessive compulsive disorder prevalence of compulsive acts that do not respond to drug treatment but to electroconvulsive therapy.

Methods Presentation and review of a case.

Results A 55-year-old woman diagnosed with recurrent depressive disorder with worsening in the last 4 years. Clinical depressive Sadness, spontaneous crying in the form of access, apathy, isolation and clinofilia desires, complaints mnemonic deficits and complete anhedonia. Obsessional symptoms compulsive as more repetitive behaviors of obsessive ideas, which repeats incessantly despite checking, that does not prepare or calm. The patient has not responded to any pharmacological strategy, despite using full doses and combinations of antidepressant, but euthymics more antipsychotics (sertraline, fluoxetine, reboxetine, venlafaxine, bupropion, lithium, valproic acid, lamotrigine, risperidone, quetiapine, trifluoperazine, clop平apine). For this reason, it was decided to start treatment with ECT, progressively responds in each session, after 8 sessions the patient is euthymic, it has resumed normal activities, no obsessive or psychotic symptoms.

Conclusions It is important to know that it is a safe technique that would save not only an economic cost, if not a personal emotional cost. It is noteworthy that more than 50% of depressed patients who respond to a course of ECT, fall between 6 and 12 months despite receiving adequate pharmacological treatment then so we will have to closely monitor the patient.

Disclosure of interest The authors have not supplied their declaration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.703

EV0374
Clinical predictors of antidepressant response to ketamine in unipolar treatment-resistant depression

Federal University of São Paulo, Psychiatry, Sao Paulo, Brazil
* Corresponding author.

Introduction The non-competitive N-methyl-D-aspartate receptor antagonist ketamine has been shown to have rapid antidepressant effects in treatment-resistant depression (TRD). However, only a few studies have investigated which clinical characteristics predict a response to ketamine.

Objectives To assess sociodemographic variables and clinical markers that predict response to ketamine in unipolar TRD patients.

Methods Searches of Pubmed, NCBI and Google Scholar were conducted for clinical trials and systematic reviews, through October 2016, using the keywords: ketamine, N-methyl-D-aspartate receptor antagonist, rapid-acting antidepressant, depression, treatment-resistant depression, clinical predictors.

Results Findings support the following clinical predictors: